Basit öğe kaydını göster

dc.contributor.authorGül, Murat
dc.contributor.authorŞerefoğlu, Ege Can
dc.date.accessioned2019-12-23T05:49:42Z
dc.date.available2019-12-23T05:49:42Z
dc.date.issued2019en_US
dc.identifier.citationGül, M. ve Şerefoğlu, E. C. (2019). Oxytocin antagonists: The next frontier in PE treatment. Nature Reviews Urology, 16(12), 696-697. https://doi.org/10.1038/s41585-019-0238-7en_US
dc.identifier.issn1759-4812
dc.identifier.issn1759-4820
dc.identifier.urihttps://doi.org/10.1038/s41585-019-0238-7
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4587
dc.description.abstractOxytocin antagonists seem to have potential as a treatment option for premature ejaculation (PE), but the parameters of their use are vague. Two recently published studies highlight the need for large-scale trials to elucidate the value of these drugs in the treatment of PE.en_US
dc.language.isoengen_US
dc.publisherNature Publishing Groupen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectIntravaginal Ejaculatory Latencyen_US
dc.subjectPremature Ejaculationen_US
dc.subjectDouble-Blinden_US
dc.subjectReceptor Antagonisten_US
dc.subjectMenen_US
dc.subjectCligosibanen_US
dc.subjectEfficacyen_US
dc.subjectSafetyen_US
dc.titleOxytocin antagonists: The next frontier in PE treatmenten_US
dc.typeeditorialen_US
dc.relation.ispartofNature Reviews Urologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Histoloji ve Embriyoloji Ana Bilim Dalıen_US
dc.authorid0000-0002-2530-7012en_US
dc.identifier.volume16en_US
dc.identifier.issue12en_US
dc.identifier.startpage696en_US
dc.identifier.endpage697en_US
dc.relation.publicationcategoryMakale - Uluslararası - Editör Denetimli Dergien_US
dc.identifier.doi10.1038/s41585-019-0238-7en_US
dc.identifier.wosqualityQ1en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster